Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects

Author(s): Avineesh Singh, Preeti Patel, Vijay K. Patel, Deepak K. Jain, Ravichandran Veerasamy, Prabodh C. Sharma, Harish Rajak*

Journal Name: Current Cancer Drug Targets

Volume 17 , Issue 5 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Colorectal cancer is a devastating disease with a dismal prognosis which is heavily hampered by delayed diagnosis. Surgical resection, radiation therapy and chemotherapy are the curative options. Due to few therapeutic treatments available i.e., mono and combination therapy and development of resistance towards drug response, novel and efficacious therapy are urgently needed.

Objective: In this study, we have studied the potential of histone deacetylase inhibitors in colorectal cancer.

Results: Histone deacetylase inhibitors (HDACIs) are an emerging class of therapeutic agents having potential anticancer activity with minimal toxicity for different types of malignancies in preclinical studies. HDACIs have proven less effective in monotherapy thus the combination of HDACIs with other anticancer agents are being assessed for the treatment of colorectal cancer.

Conclusion: The molecular mechanism emphasizing the anticancer effect of HDACIs in colorectal cancer was illustrated and a recapitulation was carried out on the recent advances in the rationale behind combination therapies currently underway in clinical evaluations.

Keywords: Colorectal cancer, fluoropyrimidines, HDAC inhibitors, kinase inhibitors, proteasome inhibitors, topoisomerase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 17 May, 2017
Page: [456 - 466]
Pages: 11
DOI: 10.2174/1568009617666170109150134
Price: $65

Article Metrics

PDF: 43
PRC: 2